STANDARD MMR BCR-ABL MAJOR

Clinical implication

The BCR-ABL1 MAJOR fusion gene is found in 95 % of patients with chronic myeloid leukemia. This chromosomal abberation leads to dysregulation of tyrosine kinase cascade resulting in the manifestation of leukemia. Patient response to treatment as well as minimal residual disease is monitored on a standardized basis through quantification of the BCR-ABL1 MAJOR b2a2 (e13a2) and b3a2 (e14a2) transcripts relative to the number of control gene ABL1 transcripts. STANDARD MMR BCR-ABL MAJOR (Cat.No 3280), verified by the National Reference Laboratory for DNA Diagnostics (Institute of Hematology and Blood Transfusion, Prague, Czech Republic), enables conversion to the international scale of treatment response (IS).

Principle of detection

STANDARD MMR BCR-ABL MAJOR is RNA standard representing **defined ratio of BCR-ABL1 MAJOR copies on the background of the reference gene (ABL1, GUSB) at the major molecular response level (MMR).** To convert the BCR-ABL MAJOR results to IS, it is necessary to include the STANDARD in the analysis.

CE IVD

Available products

Cat. No.	Product	Package size
3280-004	STANDARD MMR BCR-ABL MAJOR	4 x 20 µl (add 5 µl/rxn)

Parameters of the diagnostic kit

- ***in vitro*** **diagnostics**
- **CE IVD marked**
- **certified for transfer the result to IS**
- **RNA standard**

Validated for cyclers

- **Rotor-Gene 3000 (Corbett Research)**
- **CFX96/CFX96 Touch (Bio-Rad)**
- **Light Cycler 480/Cobas z480 (Roche Diagnostics)**
- **QuantStudio 5 (Applied Biosystems)**